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The Commission Fédérale pour les Vaccinations (CFV; Federal Vaccination Commission), the Swiss
National Immunization Technical Advisory Group (NITAG), was established in 2004 and is comprised
of 15 core members and a few ex ofﬁcio members. Its role is to serve as a scientiﬁc advisor to the author-
ities in making vaccination recommendations, and to act as a mediator between the authorities, experts,
and the public on questions concerning vaccinations. The CFV requires all members to describe in detail
any potential conﬂicts of interest. The CFV meets approximately ﬁve times per year, and the meetings’
scope covers all questions concerning immunization. Economic considerations are taken into account
when formulating recommendations. The committee disseminates data and information about its activ-
ities to the medical profession and the public using press releases, publications, factsheets and a website.
Increasing public fears about adverse effects from vaccines has resulted in vaccinations being delayed
or not given at all. Swiss health authorities consider it of great importance to clearly explain how their
de an
. recommendations are ma
. Description and background
Vaccination recommendations were published by the FOPH as
arly as 1963. These recommendations have always been estab-
ished in adherence with the federal law on epidemics [1], and in
ooperation with a group of experts to ensure that they are reg-
larly updated and that the exacting scientiﬁc criteria are met.
nitially, advice was provided by a vaccination commission within
he Société Suisse de Médecine Interne (SSMI, Swiss Society of
nternal Medicine). In the 1980s, this commission was integrated
nto the FOPH and named the Commission Suisse pour les Vaccina-
ions (Swiss Vaccination Commission). As the importance andwork
oad of this commission kept growing, it was ultimately necessary
o replace it with a federal commission, which was established
y the Federal Department of Home Affairs (FDHA) with a clear
ission statement. Thus, this new commission could perform its
dvisory function with greater independence.
Abbreviations: CFV, Federal Vaccination Commission; FOPH, Federal Ofﬁce of
ublic Health; FDHA, Federal Department of Home Affairs; NITAG, national immu-
ization technical advisory group; SSMI, Swiss Society of Internal Medicine; WHO,
orld Health Organization.
∗ Tel.: +41 31 323 87 15; fax: +41 31 323 87 95.
E-mail address: virginie.masserey@bag.admin.ch.
264-410X © 2010 Elsevier Ltd.
oi:10.1016/j.vaccine.2010.02.033
Open access under CC BY-NC-ND license. d how the CFV is crucial in this process.
© 2010 Elsevier Ltd.
The success of vaccines has reduced public fear of some dis-
eases. However, public fear of the side effects of vaccines, real
and perceived, is increasing despite continuous improvements in
the quality and regulation of vaccines. These public concerns have
resulted in childhood vaccinations being delayed or even not given
at all, resulting in potentially serious consequences for the individ-
ual and the community at large (e.g., there were recent measles
outbreaks in various Swiss cantons and neighboring countries).
Adding to this problem, health authorities are constantly adapt-
ing vaccination recommendations as new data become available,
which contributes to public confusion. To address these issues,
health authorities need to be able to clearly explain how their
recommendations are developed. The Commission Fédérale pour
les Vaccinations (CFV; Federal Vaccination Commission), the Swiss
National Immunization Technical Advisory Group (NITAG), is cru-
cial to this process because it serves as an advisor to health
authorities, and bases its recommendations on constantly updated
scientiﬁc data.
The CFV was established on 2 July 2004 by the Federal Coun-
cilor in charge of the Federal Department of Home Affairs (FDHA).
Open access under CC BY-NC-ND licenseThe CFV was originally proposed by the Director of the Federal
Ofﬁce of Public Health (FOPH). The Federal Councilor created this
expert commission to address the ever-increasing complexity of
vaccination issues. The CFV is charged with two main tasks: (1)
to be a scientiﬁc advisor to the health authorities for formulating
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Table 1
Field of expertise and professional afﬁliation of current core members of the CFV,
appointed from 1st January 2008 with their term in ofﬁce expiring on 31 December
2011.
Last name, ﬁrst name, profession, function Post
Siegrist, Claire-Anne, pediatrician,
immunologist, Professor of Vaccinology,
University Hospital
President
Binz, Hans, immunologist, cantonal chief
medical ofﬁcer (profession when appointed to
commission)
Vice-President
Aebi, Christoph, pediatrician, specialist in
infectious diseases, Professor, University
Hospital
Member
Anderau, Rebecca, Internal medicine specialist,
substitute cantonal chief medical ofﬁcer
Member
Bachmann, Gaudenz, Public Health specialist,
cantonal specialist in preventive medicine
Member
Diebold, Patrick, pediatrician, private practice Member
Gallacchi, Martine, internal medicine and
travel medicine specialist, private practice
Member
Heininger, Ulrich, specialist in pediatric
infectious diseases, vaccinologist, Professor,
University Hospital
Member
Landry, Pierre, internist, tropical diseases and
travel medicine specialist, private practice
Member
Marty-Nussbaumer, Annalis, pediatrician,
cantonal chief medical ofﬁcer
Member
Matter, Lukas, microbiologist, head of
laboratory
Member
Mühlemann, Kathrin, specialist in infectious
diseases and hospital hygiene, Professor,
University Hospital
Member
Rofﬂer, Jacob, general practitioner, private
practice
Member
Stronski Huwiler, Susanne, pediatrician, head
of school medicine service
Member
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•Trefny, Philipp, pediatrician, private practice Member
Vaudaux, Bernard, pediatrician, specialist in
infectious diseases, University Hospital
Member
accination recommendations and (2) to act as a major mediator
etween the authorities, experts, and the public on questions
oncerning vaccinations.
The commission consists of 15 members (although the current
ommission consists of 16 members, an exception to the usual
ractice) in order to ensure an optimal distribution of the different
rofessional backgrounds on the CFV (Table 1).
The Secretariat is based at the Federal Ofﬁce of Public Health
FOPH) in Bern. The Secretariat staff includes: Virginie Masserey
picher, a pediatrician and infectious diseases specialist; Hans-
eter Zimmermann, a medical doctor; and Catherine Bourquin, a
edical doctor.
. Terms of reference
An ofﬁcial document titled “Acte d’institution et décision de
omination” (institutional decree for nomination) was signed by
he Federal Councilor in charge of the Federal Department of Home
ffairs in 2004, and it deﬁnes the commission’s mission and struc-
ure. This document is not accessible to the public.
The commission’s mandate is to provide advice, as a consul-
ative body, to the Federal Department of Home Affairs (FDHA)
nd the Federal Ofﬁce of Public Health (FOPH) for all questions
oncerning vaccination, and to promote collaboration and synergy
etween public, semi-public, and private entities. To achieve these
bjectives, the commission is charged with the following tasks:
Counsel the FDHA and FOPH on developing and implementing
national vaccination policy as described in the national vaccina-
tion program. The purpose is to implement Article 3 of the federalS (2010) A48–A53 A49
law on epidemics as it concerns vaccine-preventable diseases,
with a particular focus on ensuring that it is in harmony with
World Health Organization (WHO) objectives.
• Collaborate with FDHA and FOPH in formulating strategic
and operational objectives, establishing priorities, developing
alternative strategies, and determining options for vaccine-
preventable diseases.
• Develop and periodically update, in collaboration with the
FOPH, national vaccination recommendations by integrating and
documenting scientiﬁc,medical, social, andpolitical aspects (vac-
cination schedules, supplements, etc.).
• Take into account the most recent scientiﬁc developments to
develop expertise and proposals for research, when needed, for
resolving existing or potential problems.
• Develop ofﬁcial positions on vaccination-related issues.
• Propose changes for vaccination recommendations to the FDHA
andFOPHwhen thereare changes in conditions, suchas indisease
incidence, or advances in current knowledge.
• Contribute to overseeing and improving the implementation of
recommendations.
• Relay information to and assist in the training of stakeholders and
target groups.
These actions are prepared through the working groups and
then discussed in plenary meetings (ﬁve or six per year). They lead
to the creationof recommendations, ofﬁcial positions, publications,
and internal decisions.
The committee decides which documents will be made public.
Plenary meeting reports are not made public because delibera-
tions of the committee are considered conﬁdential, but working
group evaluation reports are made public. To ensure transparency
and to enhance the dissemination of information, the CFV gen-
erally makes its work public. It publishes new recommendations,
ofﬁcial positions, interviews, and articles prepared by the commis-
sion members. More formally, information concerning vaccination
recommendations is included in the Swiss vaccination schedule
(general information and changes) and speciﬁc supplements (more
detailed information according to vaccine, disease or other topic).
The vaccination schedule is developed by the CFV in collabora-
tion with the FOPH and Swissmedic, the Swiss agency responsible
for approving and monitoring pharmaceuticals. It is updated
regularly to account for new vaccines, new information about
vaccine efﬁcacy and safety, changes in the epidemiological situ-
ation in Switzerland, and information collected from international
expertsworkingunder theauspicesofWHO.The recommendations
included in the vaccination schedule are developed to maximize
protection against disease in individuals and the public, while
reducing possible risks associated with vaccine administration.
Speciﬁc supplemental information is published throughout the
year and then implemented in the following year’s vaccination
schedule. The schedule is published at the beginning of each calen-
dar year, regardless of whether modiﬁcations have been made or
not.
3. Selection of members
Under its capacity as an advisor to health authorities, the CFV
plays a key role in formulating vaccine recommendations based
on the most up-to-date scientiﬁc data. Members of the CFV are
appointed by the Federal Department of Home Affairs based on
their individual expertise, but also with the aim of achieving equal
representation in terms of gender and geographical region on the
committee, as dictated by the laws on extra-parliamentary com-
missions. Because it is important that the members of the CFV have
competencies in all pertinent ﬁelds, it includes pediatricians and
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eneral practitioners, as well as specialists in internal medicine,
nfectious diseases, epidemiology, and public health (Table 1).
owever, there is nopredeﬁnedmandate onmembershipmake-up
y specialty. On the other hand,members are intentionally selected
o avoid representation of special interests of the organizations that
hey belong to. Members are appointed for one legislative mandate
four years) and can sit for a maximum of 12 years. There are also
x ofﬁcio members, which include FOPH representatives (the com-
ission’s Secretariat) and a Swissmedic representative. They can
articipate in the commission’s meetings but they have no voting
ights. Representatives of pharmaceutical companies canbe invited
opresentdata, but this occurs outsideof ofﬁcialmeetings, and they
o not participate in the meetings.
The CFV members work for the CFV without pay during their
our-year legislative mandate, which is in accordance with the
wiss “militia system” (a voluntary public work system). This is
demonstration of their commitment and belief that vaccination
ssues must be addressed at the highest levels in Switzerland. The
embers are reimbursed for travel expenses and they receive a
ominal compensation for attending meetings.
. Conﬂicts of interest
As vaccination recommendations have a signiﬁcant impact on
ublic health, the CFV aims to ensure that analyses of issues and
ata, which lead to vaccination recommendations, are carried out
ndependently and free of any direct or indirect pressure. Thus,
he CFV deems it necessary to avoid situations where personal or
nstitutional interests, whatever their nature may be (ﬁnancial or
ther), may affect the integrity or impartiality of its work. Experts
pproached forparticipation in theCFVmustdescribe indetail their
elations with the pharmaceutical industry and identify all other
otential conﬂicts of interest. To ensure maximum transparency,
he FDHA only appoints experts who are deemed to be free of such
onﬂicts of interest.
Each member of the CFV must declare any interests that could
onstitute real, potential or apparent conﬂicts of interest with
ndustry, either at the individual level or at the institutional level
i.e., the institute that themember is employed by).Membersmake
formal declaration of interest when they are appointed to the
ommission, as well as at each CFV meeting. A procedure exists for
aking action if a member or chairperson has any apparent inter-
sts regardingavaccineor interventionbeingdiscussed.Depending
n the situation, a member could be asked to refrain from partic-
pating in certain discussions or working groups, or to leave the
eeting during certain evaluations, or to be allowed to participate
ut asked to disclose publicly any interests that might be perceived
s a conﬂict. Description of the directives employed to ensure the
ntegrity and impartiality of CFV’s work can be found in the Décla-
ation d’intérêts pour les membres de la commission fédérale pour les
accinations [2] (declaration of interests formembers of the Federal
accination Commission). While members are required to respect
onﬁdentiality, they are not required to sign any documents to that
ffect.
. Process of meetings
TheCFVhasﬁveplenarymeetings per year,which are scheduled
ne year in advance, in addition to numerous working group meet-
ngs. Ad hoc sessions are possible. The meetings are held in Bern
nd are closed to the public. Minutes are available on a conﬁdential
asis to members and invited participants.
Meetings are prepared by the Secretariat of the CFV, which is
upported by the Vaccination programmes and control measures
ection of the FOPH. The Secretariat is responsible for assessing
nd providing speciﬁc budget requests (e.g., to engage an expert orS (2010) A48–A53
conduct a study). Funding is relatively limited, as it is for preven-
tive health in general. The Secretariat is responsible for preparing
the sessions (agenda and topics) in cooperation with the CFV Pres-
ident and has experts at its disposal who are capable of preparing
documents to serve as a background for committee discussions
(literature reviews, epidemiological data, etc.). These experts also
write recommendations and other communications materials. The
budget is sufﬁcient for the publication and dissemination of the
commission’s recommendations and promotional materials.
The commission’s scope covers all questions concerning vacci-
nation and immunization. It makes decisions as to whether the use
of new vaccines should be recommended or not (e.g., human papil-
lomavirus, rotavirus, zoster), and makes recommendations about
vaccination schedules, such as for the national schedule [Prevnar
(2 +1), hepatitis B virus (two doses for adolescents) and pandemic
inﬂuenza vaccines (two doses for certain population groups)]. It
recommends vaccinations for high-risk groups (e.g., chickenpox,
pneumococcus, inﬂuenza, etc.), and it also makes recommen-
dations beyond the infant schedule for all vaccine-preventable
diseases, although there is a separate independent ad hoc expert
committee on travel health, which speciﬁcally addresses vaccina-
tion recommendations for travelers. In addition, the CFV makes
recommendations about conducting additional studies to aid deci-
sionmaking, such as surveys on acceptability of individual vaccines
and economic cost-beneﬁt studies (e.g., for the hepatitis B vaccine).
As part of its role as a mediator between health authorities,
stakeholders, and the public concerning questions about vaccina-
tions, theCFVmay takepositions ondiverse topics that areunder its
realm of specialties. For example, there is a brochure printed by the
Stiftung fürKonsumentenschutz (Foundation for ConsumerProtec-
tion) that some parents have consulted for additional information
on vaccination. This foundation has historically been perceived as
a reputable information source, and thus this brochure was per-
ceived as a balanced source of information. In 2005, a group of
pediatric infectious disease specialists found that this brochure
was not factually sound. Subsequently, they spent a consider-
able amount of time gathering information in order to accurately
respond to issues raised in the brochure. Their response was pub-
lished in the Bulletin of the Association of Swiss Physicians (FMH),
and was subsequently distributed by CFV to physicians. Available
on the Internet, it informs the public on the non-objectivity of the
brochure as it relates to vaccination questions. Indeed, a group of
experts made up of members of the CFV has provided responses
to questions raised by the brochure in a document titled Guide sur
les vaccinations: évidences et croyances [3] (a guide for vaccinations:
evidence and beliefs).
Preparation of meetings, including setting agendas and propos-
ing areas of work, is shared between the committee and the
Secretariat under the auspices of FOPH, within the Federal Depart-
ment of Home Affairs. FOPH and external bodies can make
suggestions but cannot impose them; theoretically, proposals can
come from different political or medical groups, such as medical
societies concerned with occupational health.
At each meeting, the CFV identiﬁes issues for future discus-
sion. These issues may be identiﬁed during the commission’s work
meetings, or be requested by other commissions, specialist groups,
physicians or other involved parties. All topical requests that fall
under the competencies of the CFV, in particular those concerning
vaccines, prevention strategies and applications, can be brought to
the CFV’s attention through the Secretariat.6. Development of recommendations and the basis for
decision making
Vaccination recommendations must be based on scientiﬁc evi-
dence, integrating whenever possible a hierarchical classiﬁcation
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ystem for study validity. This analytical framework is used as a
oundation for discussions within the CFV, as well as for approach-
ng the federal commission concerning the beneﬁts of compulsory
ealth insurance. The potential beneﬁts of each vaccine for individ-
al andpublic health are identiﬁedby theCFV, in collaborationwith
he FOPH, after a rigorous assessment of numerous parameters in
esponse to a series of analytical questions.
The working group for new vaccines has decided to develop
n analytical framework allowing for a systematic and exhaustive
ssessment of all factors pertinent to the decision-making process
nd ultimately for the recommendation of a vaccine. A similar pro-
ess was already established in Quebec and was made available to
he commission. Quebec’s process was adapted to Swiss needs and
s comprised of a series of essential questions as well as a list of
lements requiring analysis.
The questions are as follows [4]:
Do the properties of the vaccine allow for the establishment of an
efﬁcacious and safe recommendation?
Will the proposed recommendation be able to attain the estab-
lished objective?
Is the cost-efﬁcacy ratio of the proposed recommendation rea-
sonable and comparable to other health interventions?
Does the proposed vaccination recommendation respond to a
strong demand?
Will the recommendation be well-received?
Can the proposed recommendation be implemented?
Can the various aspects of the proposed recommendation be
evaluated? Can important outstanding questions inﬂuence the
implementation of the proposed recommendation?
Does the proposed recommendation ensure equal access to the
vaccine for all target populations?
Can legal issues inﬂuence the implementation of the proposed
recommendation?
Does the proposed recommendation conform to existing or
planned national and international recommendations?
Using answers to these questions as a basis, the CFV has estab-
ished four categories of vaccines for recommended use:
. Basic vaccines – they are essential to individual and public
health, andoffer a level of protection that is indispensable topeo-
ple’s well-being (e.g., diphtheria, tetanus, pertussis, polio, MMR,
HBV, HPV). Physicians must recommend these vaccines to their
patients in accordance with the Swiss vaccination schedule.
. Complementary vaccines – they maximize individual protec-
tion and are meant for individuals seeking protection from
well-deﬁned risks (e.g., conjugate pneumococcal vaccine and
conjugate meningococcus C vaccine). Physicians must inform
their patients of the existence of these vaccines in accordance
with the Swiss vaccination schedule.
. Vaccines for high-risk groups – they are vaccines for people who
are likely to beneﬁt from their administration. Physicians must
make the necessary efforts to reach high-risk people to recom-
mend these vaccines in accordance with the Swiss vaccination
schedule.
. Vaccines that have not been recommended for use – they have
not yet been subjected to formal assessment, or the beneﬁts
demonstrated by the assessment are insufﬁcient to justify their
recommendations. These vaccines are on the market and can
be used but they are not subject to ofﬁcial recommendation. If
there is anyassessmentby the commissionon thesevaccines, the
physiciansand thegeneralpopulationwill be informedabout the
possible beneﬁts.S (2010) A48–A53 A51
Vaccines recommended in the categories 1, 2, and 3 are also
assessed to determine the public health interest of their integration
into the Health Care Beneﬁts Ordinance (Article 12) (vaccines tar-
geting travelers are not considered). Such a request for integration
would then be evaluated by appropriate independent commissions
(see below).
The commission obtains technical data and expertise for delib-
eration from a variety of sources, including ofﬁcial commission
members, national reference centers such as the national inﬂuenza
center or the inﬂuenza working group, and invited national ad hoc
experts. Use is made of WHO position papers, as well as national
position statements and information found on websites, such as
the European Centre for Disease Surveillance and Control (ECDC)
and the U.S. Centers for Disease Control and Prevention (CDC).
Recommendations from other NITAGs such as the U.S. Advisory
Committee on Immunization Practices are taken into account.
Working groups set upby the commission are apreferred source
of information and expertise (Table 2), some of which are perma-
nent, while others are set up for a speciﬁc period of time. They
provide a foundation for decisions in adherence with the analyt-
ical framework (see above). Membership in a working group is
voluntary and is decided upon by the commission members; any
commission member can chair and participate in a working group.
External experts canbe invited to join aswell. People fromthephar-
maceutical industry may be consulted but they cannot participate
in a working group. The working group creates a basic document
that functions as a strategic pre-position statement. It is then cir-
culated among the membership of the commission. Members can
ask questions and give feedback, after which the document is pre-
sented in a plenary meeting. The Secretariat veriﬁes the references
used, as well as independence of the work.
In making its assessments, the commission considers the fol-
lowing vaccine-preventable outcomes, which are ranked in order
of descending importance:mortality, hospitalizations, overallmor-
bidity, epidemic potential, and equity and disability-adjusted life
years (DALYs) or quality-adjusted life years (QALYs) lost. Disease
burden is an evaluated criterion for each vaccine, but there are no
predeﬁned limits on criteria. The criteria are ad hoc, and are made
according to the disease and on the synthesis of all available data. A
vaccine is recommended only if its beneﬁts, in terms of morbidity
and mortality (diseases and their complications), are signiﬁcantly
greater than the risk of it causing adverse effects.
Recommendations are usually decided upon by open vote, but
occasionally a secret vote may be held. If experts do not agree
on issues, they are resolved on a case-by-case basis. There has
never been a case where the commission has failed to follow
WHO recommendations for vaccine use, but there are cases where
the recommendations needed to be adapted to the local situa-
tion. Indeed, the commission evaluates numerous issues, including
the speciﬁcities of national epidemiology, organizational and legal
issues, acceptance or feasibility of different implementation strate-
gies, etc. Once the decisions are made, the recommendations are
transmitted directly to the FOPH by the Secretariat, which is a
part of FOPH. The recommendations are made public via ofﬁcial
publications, the website, and through press releases.
The work of the CFV falls within a national and international
context, and brings together numerous partners with the shared
objective of improving individual and public health by prevent-
ing infectious diseases and their transmission. Responding to this
context involves relationships with NITAGs in other countries,
although there is no formal mechanism for this. The interactions
among the CFV and other NITAGs during WHO conferences, meet-
ings and other forums tend to be informal and personal. Some
members of the Swiss committee are also members of other
committees, but any information they obtain from the other com-
mittees falls under the conﬁdentiality requirement of the CFV.
A52 V.M. Spicher / Vaccine 28S (2010) A48–A53
Table 2
Topics that have been or are being investigated by CFV’s working groups.
Titles of topics under investigation Start date Anticipated duration at
the time of initiation
Hepatitis A and B vaccination recommendations
Working group studying recent epidemiological data, including vaccination
recommendations
06/2005 6 months
Vaccinations for health professionals
Working group updating vaccination recommendations for health professionals and
students
06/2005 6 months
2006 vaccination schedule
Working group responsible for preparing the upcoming vaccination schedule
04/2005 8 months
Vaccination documentation
Working group preparing documents on vaccination information
01/2005 12 months
Vaccinations and pregnancy
Working group updating recommendations for vaccination before, during and after
pregnancy
01/2005 12 months
Tick-borne encephalitis vaccine (FSME)
Working group preparing new vaccination recommendations (particularly booster
frequency)
11/2004 12 months
Communications
Working group studying CFV communications methods
9/2004 Permanent
Adverse effects of vaccines
Working group responsible for issues concerning the surveillance, reporting, analysis, and
9/2004 Permanent
7
t
a
c
a
i
w
h
e
a
t
o
g
n
b
a
i
e
w
t
i
c
v
e
e
b
l
v
i
8
u
m
acommunication of adverse effects of vaccines
New vaccines
Working group responsible for assessing new vaccines
. Role of economic analysis in decision making
Economic considerations have a place in committee delibera-
ions, beginning with the issue of the cost of the vaccine. Economic
nalysis is done on a case-by-case basis to assess cost-effectiveness,
ost-beneﬁt and cost-utility, as well as the overall affordability
nd sustainability of the immunization program. However, there
s no benchmarking (i.e., no predeﬁned threshold). The issue of
hether or not the vaccine should be reimbursed through social
ealth insurance is also addressed.
The committee does not have immediate access to health
conomics experts, and therefore, economic analyses consist of
pproximate estimations, literature reviews, or work outsourced
o external companies. The evaluation process takes approximately
ne year, and decisions are made on a case-by-case basis. When
eneral vaccinations are being considered, the time taken for eco-
omic analysis is even longer.
The committeeuses results from international economic studies
ut assesses them for possible differences under the Swiss context,
s well as for possible differences compared with its own stud-
es. Pharmaceutical companies andmanufacturers can also provide
conomic assessments, but in this case, the committee consults
ith an independent expert to verify the reliability of their assump-
ions and calculations.
Economic evaluations are used in different ways by the CFV
n the decision-making process. For example, if the vaccine’s
ost-utility ratio compares favorablywith that of otherhealth inter-
entions, it constitutes an additional favorable point in the global
valuation. On the contrary, if the vaccine is considered to be very
xpensive compared to its beneﬁts, it is unlikely that itwill be reim-
ursed by health insurance. Thus, recommending the vaccine may
ead to health inequities as only persons who can afford to buy the
accine will be able to follow the vaccine recommendation if it is
ssued by the CFV.
. Role of the committee and other key players in the
ltimate decision-making process
The role of the commission is advisory; in practice, the govern-
ent has always followed CFV’s recommendations, either immedi-
tely or after clariﬁcation of questions concerning implementation,9/2004 Permanent
organization, ﬁnancing, and other issues. In Switzerland, new
vaccines are registered and distributed at the request of phar-
maceutical companies after marketing authorization is granted
by Swissmedic. This marketing authorization is independent of
national recommendations that could be possiblymade by CFV and
FOPH. After an ofﬁcial recommendation has been made, the FDHA
then makes a decision on integration of the vaccine on to the list
of services reimbursed by health insurance, after consultation has
beenmadewith theCommission fédérale des prestations générales
(federal commission for general services). Currently there are
several (new) vaccines available on the market that are not rec-
ommended by the FOPH (rotavirus, herpes zoster), or vaccines that
are only recommended and reimbursed for certain at-risk groups
(hepatitis A).
The FOPH also oversees social health insurance. This function of
the FOPH sets reimbursement levels for pharmaceuticals, after con-
sultation with the Commission fédérale des médicaments (federal
commission for pharmaceutical products). This process involves
comparing prices with those applied in neighboring countries, as
well as negotiating prices with manufacturers. Cantonal authori-
ties can also play a role, as they are responsible for implementation
and they can conduct purchase-price negotiations for cantonal pro-
grams.
Occasionally, the effect of external, contextual inﬂuences can be
signiﬁcant, and the case of the HPV vaccine is a very good example
of potential complexities that lie in the decision-making process. In
this instance, the HPV vaccine received heavy media coverage dur-
ing its assessment by CFV, and between the time the CFV issued its
recommendation to the public and implementation of vaccination.
The CFV wanted to make its recommendations public well before
ﬁnancing issues were settled by social health insurance because
social health insurance was hesitant about moving forward, as it
was trying unsuccessfully to negotiate a lower price for the vaccine.
A solutionwas ﬁnally foundwhereby reimbursementwas linked to
the creation of cantonal programs including a central procurement
of vaccines. However, this solution was communicated to the pub-
lic before the cantons had the chance to set up such programs. This
all resulted in creating a lot of public impatience and confusion,
and in certain circles, there were suspicions of pressure from the
pharmaceutical industry and conﬂicts of interest within the CFV.
The Parliament intervened several times as well.
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Professional organizations may take ofﬁcial positions regarding
peciﬁcvaccinesandprograms, and thesearedulynotedby theCFV.
anufacturers and representatives of the pharmaceutical industry
an be invited to provide information to the CFV but only outside
f ofﬁcial commission meetings. None of these groups provide any
unding or material support of any kind to the CFV or its members.
. Communications activities and training practices
The committee disseminates data and information about its
ctivities to the medical profession and the public using a vari-
ty of means. Press releases, and other government publications
nd decrees are supplemented by publications jointly issued by the
ommittee and the FOPH, such as chapters of its handbook titled
irectives and recommendations [5], aswell as individual factsheets.
he FOPH partially funds an electronic newsletter called Infovac
hat serves as an expert information site, and itmaintains awebsite.
hese all contribute todisseminatingofﬁcial recommendations and
nswers to questions from medical professionals.
Pharmaceutical or private companies, including insurance
ompanies, occasionally distribute CFV brochures or relay CFV
ecommendations in their own brochures. Information is also
isseminated at professional medical meetings. Members of the
ommittee communicatewith each other atmeetings and via email
nd conference calls. Information is shared with other NITAGs
nformally.
0. Challenges and limitations
The committee’s work has sometimes experienced certain lim-
tations, such as lack of available funding for conducting studies,
ack of sufﬁcient expertise available to the committee relating to
conomic analysis, or insufﬁcient human resources for the timely
pdating of some of the CFV’s recommendations. There is also lim-
ted coordination between the division of the FOPH, which issues
he ofﬁcial recommendations concerning vaccines and immu-
ization, and the division whose responsibility is to assess the
ntegration of these services into health insurance beneﬁts. Suf-
cient coordination can also be found lacking between the federal
ealth authorities, which are responsible for the vaccination rec-
mmendations and the decisions regarding reimbursement, and
he cantonal health authorities, which are responsible for imple-
entation of the necessary measures.
As mentioned above, new vaccines are registered and dis-ributed in Switzerland following requests by the pharmaceutical
ndustry after marketing authorization is granted, independent of
FV or FOPH recommendations. The FDHA then decides on the vac-
ine’s integration into the compulsory health insurance program
fter consultation with the Commission fédérale des prestations
[
[S (2010) A48–A53 A53
générales (Federal Commission for General Services). Thus, several
new vaccines that are available on the market are only recom-
mended by the FOPH for certain high-risk groups. This calls into
question the possibility of equal access to some efﬁcacious and safe
vaccines (e.g., vaccines against tick-borne encephalitis or vaccines
for travelers).
11. Conclusion: assessment of the CFV’s work and
perspectives for the future
The decrease in public perception of the risks of infectious
diseases, and the increase in the fear of secondary effects from
vaccines, despite the continual improvement of vaccines available
on the market, has resulted in vaccination delays or refusals to
vaccinate. Toaddress this issue, health authoritiesmustbe inaposi-
tion to clearly explain how their vaccination recommendations are
established. The role of the CFV is crucial to this process, and it is
well-regarded and has high credibility among health professionals
and the general public.
Inorder to further improveevidence-baseddecisionmaking, it is
crucial that appropriate resources are allocated to the CFV in order
to further improve and expedite the preparation of evidence-based
information by the working groups and by commission members
themselves prior to voting on speciﬁc topics. Likewise, improve-
ments in CFV communications activities and in the disclosure of
potential conﬂicts of interest of members are needed, and they are
being addressed by the committee.
The CFV is free to express itself, giving its points of view and
explaining the basis for its recommendations whatever the opin-
ions of the federal administration may be. Thus, it is not just
“another ofﬁce in Bern,” but rather an important link in the chain of
stakeholders supporting disease prevention through vaccination.
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